Resveratrol

Generic Name: Resveratrol

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₂O_₃

CAS Number: 501-36-0

Unique Ingredient Identifier: Q369O8926L

Background: Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of...

Indication: Being investigated for the treatment of Herpes labialis infections (cold sores).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy

Phase 2

Completed

Conditions: Peripheral Diabetic Neuropathy

Interventions: Drug: Super Oxide Dismutase
Drug: Resveratrol, Alpha lipoic acid, Super oxide dismutase
Drug: Resveratrol
Drug: Alpha lipoic acid

First Posted Date: 2023-11-14

Last Posted Date: 2024-08-26

Lead Sponsor: Khyber Medical University Peshawar

Target Recruit Count: 100

Registration Number: NCT06131918

Locations: 🇵🇰
Syed Hamid Habib, Peshawar, KPK, Pakistan

Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency

Not Applicable

Conditions: Primary Ovarian Insufficiency

Interventions: Drug: Vitamin E
Drug: Resveratrol

First Posted Date: 2022-06-08

Last Posted Date: 2022-06-08

Lead Sponsor: Affiliated Hospital of Nantong University

Target Recruit Count: 150

Registration Number: NCT05410093

Locations: 🇨🇳
B ultrasound, Nantong, Jiangsu, China

Effect of Resveratrol and Pharmacist Intervention on Diabetes Mellitus and Its Neuropathic Complication

Not Applicable

Completed

Conditions: Diabetic Neuropathies

Interventions: Drug: Placebo
Other: Resveratrol plus Pharmaceutical care
Other: Placebo+Pharmaceutical care
Drug: Resveratrol

First Posted Date: 2021-12-29

Last Posted Date: 2023-03-14

Lead Sponsor: University of Sulaimani

Target Recruit Count: 120

Registration Number: NCT05172947

Locations: 🇮🇶
College of Pharmacy-University of Sulaimani, Sulaymānīyah, Iraq

The Anti-fibrotic Therapeutic Effects of Resveratrol for Discharged COVID-19 Patients

Not Applicable

Conditions: Covid-19

Interventions: Drug: Placebo capsules
Drug: Resveratrol

First Posted Date: 2021-03-16

Last Posted Date: 2021-07-16

Lead Sponsor: Hong Kong Baptist University

Target Recruit Count: 30

Registration Number: NCT04799743

Locations: 🇭🇰
Linda Zhong, Kowloon Tong, Kowloon, Hong Kong

Nasal Resveratrol and Wheezing Episodes in Preschool Children

Completed

Conditions: Wheezing
Upper Respiratory Tract Infections

Interventions: Drug: Resveratrol

First Posted Date: 2020-12-30

Last Posted Date: 2020-12-30

Lead Sponsor: University Of Perugia

Target Recruit Count: 50

Registration Number: NCT04689412

Locations: 🇮🇹
Università di Perugia, Perugia, Italy

Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

Early Phase 1

Recruiting

Conditions: Type 1 Diabetes

Interventions: Drug: Resveratrol
Other: Placebo

First Posted Date: 2020-06-26

Last Posted Date: 2024-07-31

Lead Sponsor: Augusta University

Target Recruit Count: 24

Registration Number: NCT04449198

Locations: 🇺🇸
Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology, Augusta, Georgia, United States

Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19

Phase 2

Terminated

Conditions: COVID-19

Interventions: Dietary Supplement: Vitamin D3
Drug: Resveratrol

First Posted Date: 2020-05-26

Last Posted Date: 2023-02-24

Lead Sponsor: Marvin McCreary, MD

Target Recruit Count: 105

Registration Number: NCT04400890

Locations: 🇺🇸
Mt Carmel HealthSystems, Columbus, Ohio, United States

Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis

Early Phase 1

Recruiting

Conditions: Cystic Fibrosis

Interventions: Drug: Resveratrol
Drug: NR
Dietary Supplement: Placebo

First Posted Date: 2019-11-18

Last Posted Date: 2024-04-26

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 36

Registration Number: NCT04166396

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Micronised Resveratrol as a Treatment for Friedreich Ataxia

Phase 2

Completed

Conditions: Friedreich Ataxia

Interventions: Drug: Resveratrol

First Posted Date: 2019-05-01

Last Posted Date: 2024-05-22

Lead Sponsor: Murdoch Childrens Research Institute

Target Recruit Count: 25

Registration Number: NCT03933163

Locations: 🇦🇺
Royal North Shore Hospital, St Leonards, New South Wales, Australia
🇦🇺
University of Queensland Centre for Clinical Research, Herston, Queensland, Australia
🇦🇺
Royal Perth Hospital, Perth, Western Australia, Australia

and more 1 locations

Resveratrol Trial for Relief of Pain in Pseudoachondroplasia

Phase 2

Terminated

Conditions: Pseudoachondroplasia

Interventions: Drug: resveratrol
Drug: Placebo

First Posted Date: 2019-03-07

Last Posted Date: 2022-12-09

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 6

Registration Number: NCT03866200

Locations: 🇺🇸
University of Texas Health Science Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy